Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCD-055 vs Remicade in Ankylosing Spondylitis
NCT02359903Phase 1Completed
- Sponsor
- BIOCAD
- Start
- Feb 2015
- Primary completion
- Nov 2015
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of Zessly in ankylosing spondylitis (AS) (2 arms), sponsored by BIOCAD. Primary endpoint: Area Under the Plasma Concentration-time Curve From Zero (0) Hours to 336 Hours. Started Feb 2015; status: completed.
02
Drugs
Zessly
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NCT02359903.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02359903.